Technical Analysis for KIN - Kindred Biosciences, Inc.

Grade Last Price % Change Price Change
C 4.65 -4.12% -0.20
KIN closed down 4.12 percent on Monday, April 19, 2021, on 78 percent of normal volume.
Earnings due: May 1
*** please verify all earnings dates ***

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down
Historical KIN trend table...

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish -4.12%
Fell Below 50 DMA Bearish -4.12%
MACD Bearish Signal Line Cross Bearish -4.12%
Outside Day Range Expansion -6.44%
Narrow Range Bar Range Contraction -6.44%
20 DMA Support Bullish -5.68%
50 DMA Support Bullish -5.68%
Narrow Range Bar Range Contraction -6.81%
NR7 Range Contraction -6.81%
Upper Bollinger Band Walk Strength -7.55%
Older End-of-Day Signals for KIN ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakdown about 17 hours ago
Down 5% about 17 hours ago
Down 3% about 19 hours ago
Down 2 % about 20 hours ago
Down 1% about 20 hours ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Kindred Biosciences, Inc. Description

Kindred Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development of therapies for pets. The company is pursuing small molecules and biologics that are in various stages of development for a range of indications in dogs, cats, and horses. Its products include CereKin, an oral interleukin-1 beta inhibitor for osteoarthritis pain and inflammation in dogs; AtoKin, a beef-flavored formulation of fexofenadine for atopic dermatitis in dogs; SentiKin, an oral analgesic formulation of flupirtine to manage post-operative pain in dogs and horses; KIND-007, an inhibitor of Bruton's tyrosine kinase; and KIND-006, an agent for gastrointestinal diseases in cats. The company also has a portfolio of other drugs and biologics under development, which comprise anti-IgE antibody for allergic and immune-mediated diseases; canine analog of Enbrel for inflammatory and autoimmune diseases; canine analog of Orencia for immune-mediated diseases; and KIND-504, a cancer vaccine. Kindred Biosciences, Inc. was founded in 2012 and is headquartered in Burlingame, California.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Cancer Immunology Immune System Pain Autoimmune Diseases Inflammation Gastrointestinal Flavor Autoimmune Disease Pets Dogs Beef Osteoarthritis Tyrosine Kinase Dermatitis Atopic Dermatitis Gastrointestinal Disease Gastrointestinal Diseases Cancer Vaccine Immune Mediated Diseases Atopy Inflammatory And Autoimmune Diseases Bruton Etanercept Flupirtine Immunoglobulin E

Is KIN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 6.0
52 Week Low 3.2
Average Volume 410,113
200-Day Moving Average 4.39
50-Day Moving Average 4.87
20-Day Moving Average 4.85
10-Day Moving Average 4.99
Average True Range 0.28
ADX 21.5
+DI 23.51
-DI 21.37
Chandelier Exit (Long, 3 ATRs ) 4.89
Chandelier Exit (Short, 3 ATRs ) 5.07
Upper Bollinger Band 5.37
Lower Bollinger Band 4.34
Percent B (%b) 0.3
BandWidth 21.20
MACD Line 0.02
MACD Signal Line 0.05
MACD Histogram -0.0254
Fundamentals Value
Market Cap 183.44 Million
Num Shares 39.4 Million
EPS -1.63
Price-to-Earnings (P/E) Ratio -2.85
Price-to-Sales 3.49
Price-to-Book 1.95
PEG Ratio -0.16
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.97
Resistance 3 (R3) 4.98 4.90 4.91
Resistance 2 (R2) 4.90 4.82 4.89 4.89
Resistance 1 (R1) 4.77 4.77 4.73 4.76 4.88
Pivot Point 4.69 4.69 4.67 4.68 4.69
Support 1 (S1) 4.56 4.61 4.52 4.55 4.42
Support 2 (S2) 4.48 4.56 4.47 4.41
Support 3 (S3) 4.35 4.48 4.39
Support 4 (S4) 4.34